ARDS

Category

UCI Investigates Synthetic Vasoactive Intestinal Polypeptide-based Experimental Drug on High Risk SARS-CoV-2 Patients

University of California Irvine, (UCI) recently announced their participation in a COVID-19-focused clinical trial investigating a drug called Aviptadil in at risk patients. Dr. Richard Lee, Interim chief of UCK Health Division of Pulmonary Diseases and Critical Care...

Ansun Biopharma’s DAS181 Shows Promise in COVID-19 Patients with Respiratory Challenges

Recently, the Wall Street Journal introduced a small, 25-person San Diego-based biotech called Ansun Biophrma (Ansun) reporting on recent success of a drug that cleared COVID-19 symptoms in a small study involving four Chinese patients. With a strong background in...

Retrospective Study of COVID-19 ARDS Patients Led by San Raffaele University Points to Sobi’s Anakinra Promise: Clinical Trials Required

Researchers from Vita-Salute San Raffaele University as well as collaborative colleagues recently concluded a small retrospective study based in Italy focusing on the most at risk of COVID-19 patients. The mortality rates for those SARS-CoV-2 patients afflicted with...

Emergency-Access Study Saves Two Critically Ill COVID-19 Patients, and The Principal Investigator Seeks to Save More Lives

Heroes still exist in the world, and this time one took the form of a 35-year old neurologist and principal investigator named Dr. Thomas Pitts. TrialSite News recently highlighted how this physician saved the life of Amy De Vos, a 45-year old who fought for her life...

Virginia Commonwealth Commences Canakinumab Study Targeting Severe COVID-19 Patients with Pneumonia

Virginia Commonwealth University (VCU), a prominent public research university in Richmond, Virginia, became one of the first clinical investigational sites in the world to begin clinical trials to study the safety and efficacy of the Novartis drug canakinumab on...

Redhill Biopharma’s Opaganib Shows Promise Among 6 Hospitalized COVID-19 Patients in Israel via Compassionate Use Program

RedHill Biopharma Ltd (RDHL), a specialty biopharmaceutical company, reports that all six hospitalized patients with confirmed SARS-CoV-2 infection (the cause of COVID-19) that received their experimental drug opaganib (Yeliva®) demonstrated measurable clinical...

Patient’s Life Saved by Small Trial led by Hudson Health’s Dr. Tom Pitts’ Investigation into Eculizumab for Severe COVID-19 Cases

Amy De Vos was fighting for her life. The 45-year-old out of a small town called Troy, Ohio (near Dayton) was in critical condition—spending 29 days in Upper Valley Medical Center with COVID-19. As her conditioned worsened in the hospital, her doctor, Dr. Eleina...

Yale to Launch Clinical Trial for Severe COVID-19 Patients with Ibudilast—an Asthma Medication from Japan

Clinical investigators at Yale-New Haven Hospital are investigating the efficacy of ibudilast (MN-166) for treating acute respiratory distress syndrome (ARDS), the life-threatening condition developed by some of the most severe cases seen in COVID-19 patients. These...

The FDA Approving Experimental Stem Cell Therapies Targeting Patients with Severe COVID-19 Cases

Novel medical innovations are being pursued by biotech companies and clinical investigators to halt COVID-19 causalities as there is, presently, no approved treatment for the novel coronavirus—especially in severe, escalated conditions where mortality is more...

Austrian Biotech’s Investigational Phase II Drug Receives Compassionate Use Approval for COVID-19 ARDS

About 20% of those hospitalized with COVID-19 suffer from acute respiratory distress syndrome (ARDS), a potentially life-threatening complication of the infection with SARS-CoV-2. Consequently, an Austrian biotech has received compassionate use approval from the...